Jeroen Mebis

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer

Abdelbari Baitar, Frank Van Fraeyenhove, A. Vandebroek et al. · Journal of Geriatric Oncology · 2012 · 136 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

Antonio Llombart‐Cussac, Antonio Frassoldati, Outi Paija et al. · Clinical Breast Cancer · 2011 · 131 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Adam Brufsky, S.B. Kim, Zanete Zvirbule et al. · Annals of Oncology · 2021 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17